All Stories

  1. Clinical care for patients with elevated lipoprotein(a) in Canada: a practical framework for screening, risk assessment and management.
  2. Vaccination in Patients with Cardiovascular Disease: A Case-Based Approach and Contemporary Review
  3. Characterization of lipoprotein (a) testing in Alberta, Canada: a retrospective cohort study
  4. Prevention and Management of Cardiovascular Disease in Primary Care: A Comment on the PEER Simplified Lipid Guideline
  5. Assessment of immunosuppression induction with basiliximab compared to antithymocyte‐globulin in adult heart transplant patients
  6. Increased Lp(a) Workload Volumes Reflect Uptake of the 2021 Canadian Cardiovascular Society Guidelines for Management of Dyslipidemia
  7. Pharmacist-Led Follow-Up Program for Rural Patients with Acute Coronary Syndrome: The PLURAL-ACS Pilot Program
  8. Consideration and Application of Lipoprotein(a) in the Risk Assessment of Atherosclerotic Cardiovascular Disease Risk in Adults
  9. Explaining the TG cut-off in the 2021 lipid guidelines for when clinicians should rely on non-HDL-C or ApoB
  10. Updated guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacists
  11. Ligne directrice C-CHANGE pour l’harmonisation des lignes directrices nationales de prévention et de prise en charge des maladies cardiovasculaires en contexte de soins primaires au Canada: mise à jour 2022
  12. Canadian Cardiovascular Harmonized National Guideline Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2022 update
  13. Omega-3 fatty acids for cardiovascular disease prevention: A practice tool for pharmacists
  14. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults
  15. Lipid therapy: A new whiteboard video for patient education
  16. Association Between Hemoglobin A1c and Major Adverse Coronary Events in Patients with Diabetes Following Coronary Artery Bypass Surgery
  17. Comparison of Preventive Cardiovascular Pharmacotherapy in Surgical vs Percutaneous Coronary Revascularization
  18. INTER PROFESSIONAL TEAM-BASED SYSTEMATIC EVALUATION AND MANAGEMENT OF LIPIDS IN CARDIAC REHABILITATION PATIENTS WITH CORONARY ARTERY DISEASE
  19. The 2018 ACC/AHA Lipid Guidelines: A Little More or Less Canadian?
  20. Switching to Clopidogrel in Patients With Acute Coronary Syndrome Managed With Percutaneous Coronary Intervention Initially Treated With Prasugrel or Ticagrelor: Systematic Review and Meta-analysis
  21. Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY OUTCOMES Trial
  22. Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018
  23. Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update
  24. Remote Pharmacist Practice Model of Collaboration in Primary Care
  25. Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events
  26. Prevention and management of statin adverse effects: A practical approach for pharmacists
  27. Pharmacologic Treatment of Patients With Myocardial Ischemia With No Obstructive Coronary Artery Disease
  28. Systematic review of the evidence for the use of DOAC's in patient with a heart transplant.
  29. Comment: Should an LDL Cholesterol Target–Based Approach Be Readopted?
  30. PHARMACOLOGICAL TREATMENT OF PATIENTS WITH ANGINA WITH NO OBSTRUCTIVE CORONARY ARTERY DISEASE (ANOCA): A SYSTEMATIC REVIEW
  31. The Past, the Present, and a Very Bright Future
  32. Dyslipidemia Treatment Guidelines
  33. La recherche de l’excellence en pratique professionnelle et l’obtention de la reconnaissance des pairs
  34. The Pursuit of Professional Practice Excellence and the Achievement of Peer Recognition
  35. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult
  36. New Antilipid Drugs: Do the Known Benefits Justify the Expense?
  37. A randomized trial of a community-based approach to dyslipidemia management
  38. Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016)
  39. Faire partie de la SCPH – un investissement dans votre avenir et celui de la pharmacie hospitalière!
  40. Belonging to CSHP—An Investment in Your Future and That of Hospital Pharmacy!
  41. Evaluation of the Management of Hyperlipidemia and Hypertension in an Outpatient Cardiac Transplant Clinic
  42. Death to the Print Format—But Let Us Not Forget Our Past
  43. Un changement de saison, un nouveau départ!
  44. A Change of Seasons—A New Beginning!
  45. Correlation of cardiovascular magnetic resonance imaging findings and endomyocardial biopsy results in patients undergoing screening for heart transplant rejection
  46. A New Year—Time for Reconciliation
  47. Une nouvelle année : l’heure est au bilan
  48. Professional Use of Social Media by Pharmacists
  49. Updated guidelines for the management of dyslipidemia and prevention of cardiovascular disease by pharmacists
  50. Cardiovascular MRI Predicts 5-Year Adverse Clinical Outcome in Heart Transplant Recipients
  51. L’art de la planification
  52. The Art of Planning
  53. Adverse drug reactions
  54. Are the ACC/AHA Guidelines on the Treatment of Blood Cholesterol a Game Changer? A Perspective From the Canadian Cardiovascular Society Dyslipidemia Panel
  55. Non-Immunosuppressant Medication Use in Heart Transplant Patients: A Guide for Pharmacists
  56. Evaluation of Preventive Cardiovascular Pharmacotherapy after Coronary Artery Bypass Graft Surgery
  57. Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Working Group Consensus Update
  58. 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult
  59. An Evaluation of Teaching Physical Examination to Pharmacists
  60. An evaluation of teaching physical examination to pharmacists
  61. Research Grants from the CSHP Research and Education Foundation
  62. A Systematic Review of the Evidence for Pharmacist Care of Patients With Dyslipidemia
  63. Frequency of Intensive Statin Therapy in Patients With Acute Coronary Syndrome Admitted to a Tertiary Care Center
  64. Secondary Stroke Prevention: Practice Patterns in a Tertiary Care Stroke Service
  65. Prescribing by Pharmacists and Collaborative Care: Are We Ready to Accept the Baton and Get in the Race?
  66. Making Hospital Pharmacists Indispensable on the Healthcare Team: Revolution in Waiting
  67. Colchicine for the Primary and Secondary Prevention of Pericarditis: An Update
  68. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations
  69. Impact of Pharmacist Interventions in Patients with Dyslipidemia: A Systematic Review
  70. Monitoring of mycophenolate mofetil in orthotopic heart transplant recipients—a systematic review
  71. Macrolide Antibiotics and Calcineurin Inhibitors: Avoiding a Far too Common Drug Interaction in Transplant Patients
  72. Guidelines for the Management of Dyslipidemia and Prevention of Cardiovascular Disease by Pharmacists
  73. Gaps, Goals and Getting to Target: A Call to Action for Pharmacists!
  74. Maintenance of improved lipid levels following attendance at a cardiovascular risk reduction clinic: a 10-year experience
  75. Optimizing Healthcare at the Population Level: Results of the Improving Cardiovascular Outcomes in Nova Scotia Partnership
  76. 2007 guidelines for the management of dyslipidemia and prevention of cardiovascular disease by pharmacists
  77. Evolution in the practice of pharmacy--not a revolution!
  78. New advances in antirejection therapy
  79. Clopidogrel-Precipitated Rhabdomyolysis in a Stable Heart Transplant Patient
  80. The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic
  81. Pretransplant Diabetes, Not Donor Age, Predicts Long-Term Outcomes in Cardiac Transplantation
  82. Author's Reply
  83. Comment: supratherapeutic response to ezetimibe administered with cyclosporine
  84. Supratherapeutic Response to Ezetimibe Administered with Cyclosporine
  85. Long-Term Impact of a Community Pharmacist Intervention on Cholesterol Levels in Patients at High Risk for Cardiovascular Events: Extended Follow-up of the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus)
  86. Is oral azithromycin effective for the treatment of cyclosporine-induced gingival hyperplasia in cardiac transplant recipients?
  87. Use of OTC and Herbal Products in Patients with Cardiovascular Disease
  88. The Importance of In-Hospital Statin Therapy for Patients with Acute Coronary Syndromes
  89. Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events
  90. Assessment of new onset postcoronary artery bypass surgery atrial fibrillation: current practice pattern review and the development of treatment guidelines
  91. Evaluation of the use of evidence-based angiotensin-converting enzyme inhibitor criteria for the treatment of congestive heart failure: opportunities for pharmacists to improve patient outcomes
  92. Case Report: I reatment of Blastomycosis with Fluconazole